Vestmark Advisory Solutions Inc. Purchases 30,541 Shares of DexCom, Inc. (NASDAQ:DXCM)

Vestmark Advisory Solutions Inc. grew its holdings in DexCom, Inc. (NASDAQ:DXCM) by 555.0% in the fourth quarter, HoldingsChannel reports. The fund owned 36,044 shares of the medical device company’s stock after buying an additional 30,541 shares during the period. Vestmark Advisory Solutions Inc.’s holdings in DexCom were worth $4,473,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Valley National Advisers Inc. boosted its position in shares of DexCom by 73.0% in the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after acquiring an additional 103 shares during the period. MV Capital Management Inc. lifted its stake in shares of DexCom by 99.3% in the 4th quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock valued at $34,000 after acquiring an additional 138 shares during the last quarter. Washington Trust Advisors Inc. increased its holdings in DexCom by 120.6% in the 4th quarter. Washington Trust Advisors Inc. now owns 353 shares of the medical device company’s stock worth $44,000 after purchasing an additional 193 shares in the last quarter. Turtle Creek Wealth Advisors LLC bought a new position in DexCom in the fourth quarter valued at about $57,000. Finally, NBC Securities Inc. bought a new stake in shares of DexCom during the third quarter worth about $47,000. Institutional investors own 97.75% of the company’s stock.

Analyst Ratings Changes

DXCM has been the topic of a number of recent analyst reports. StockNews.com upgraded shares of DexCom from a “hold” rating to a “buy” rating in a research report on Wednesday. Raymond James lifted their price target on DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a report on Friday, April 26th. Royal Bank of Canada assumed coverage on shares of DexCom in a research report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 target price for the company. UBS Group increased their target price on shares of DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a research note on Wednesday, April 10th. Finally, Citigroup boosted their price target on shares of DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Two research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $141.67.

Insider Buying and Selling at DexCom

In related news, CEO Kevin R. Sayer sold 81,007 shares of the company’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total value of $10,803,093.52. Following the transaction, the chief executive officer now directly owns 333,526 shares of the company’s stock, valued at approximately $44,479,027.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, EVP Michael Jon Brown sold 629 shares of the business’s stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $126.25, for a total transaction of $79,411.25. Following the completion of the sale, the executive vice president now directly owns 68,212 shares in the company, valued at $8,611,765. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Kevin R. Sayer sold 81,007 shares of the firm’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total value of $10,803,093.52. Following the completion of the transaction, the chief executive officer now directly owns 333,526 shares in the company, valued at $44,479,027.36. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 190,004 shares of company stock worth $25,610,270. 0.41% of the stock is owned by insiders.

DexCom Stock Up 1.4 %

Shares of NASDAQ:DXCM traded up $1.72 during trading on Friday, hitting $128.37. The stock had a trading volume of 1,778,982 shares, compared to its average volume of 2,993,904. The company has a quick ratio of 2.53, a current ratio of 2.90 and a debt-to-equity ratio of 1.08. The company has a market capitalization of $51.05 billion, a PE ratio of 82.82, a PEG ratio of 2.16 and a beta of 1.23. The firm’s fifty day moving average is $132.11 and its 200 day moving average is $119.96. DexCom, Inc. has a 12 month low of $74.75 and a 12 month high of $142.00.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. DexCom had a net margin of 16.82% and a return on equity of 31.01%. The business had revenue of $921.00 million for the quarter, compared to analysts’ expectations of $911.20 million. Analysts anticipate that DexCom, Inc. will post 1.78 EPS for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.